71 related articles for article (PubMed ID: 10493026)
1. The effects of two different cisplatin-based chemotherapy regimens on advanced non-small cell lung cancer.
Chen CH; Yang CT; Chang WJ; Liaw CC; Tsao TC
Changgeng Yi Xue Za Zhi; 1999 Jun; 22(2):220-6. PubMed ID: 10493026
[TBL] [Abstract][Full Text] [Related]
2. Concurrent 5-fluorouracil, leucovorin, etoposide, cisplatin and radiotherapy for locally advanced non-small cell lung cancer.
Yang CT; Chang WC; Chen LH; Leung WM; Lee CH; Liaw CC
Changgeng Yi Xue Za Zhi; 1997 Sep; 20(3):187-94. PubMed ID: 9397609
[TBL] [Abstract][Full Text] [Related]
3. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
[TBL] [Abstract][Full Text] [Related]
4. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
5. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer.
Rixe O; Coeffic D; Orcel B; Maitre B; Borel C; Benhammouda A; Petit T; Khayat D; Derenne JP
Am J Clin Oncol; 1997 Apr; 20(2):128-31. PubMed ID: 9124184
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer.
Ali MA; Kraut MJ; Valdivieso M; Wozniak AJ; Cummings G; Kalemkerian GP
Cancer Invest; 2000; 18(1):1-5. PubMed ID: 10701360
[TBL] [Abstract][Full Text] [Related]
8. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
9. The combination of 5-fluorouracil, leukovorin, etoposide, and cisplatin (FLEP) in patients with metastatic esophageal cancer. A single-institution experience.
Jonak C; Raderer M; Zacherl J; Prager G; Troch M; Ba-Ssalamah A; Hejna M
Anticancer Res; 2008; 28(6B):4101-4. PubMed ID: 19192667
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine.
Polyzos A; Tsavaris N; Veslemes M; Dardoufas K; Dosios T; Kosmas C
J Chemother; 1997 Apr; 9(2):102-5. PubMed ID: 9176747
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life].
Rolski J; Zemełka T; Jasiówka M; Czyzewicz G; Kojs-Pasińska E
Pneumonol Alergol Pol; 2007; 75(4):343-8. PubMed ID: 18080983
[TBL] [Abstract][Full Text] [Related]
12. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the four combination chemotherapies in non-small cell lung cancer treated at Maharaj Nakorn Chiang Mai Hospital.
Thongprasert S
Gan To Kagaku Ryoho; 1992 Jul; 19(8 Suppl):1197-201. PubMed ID: 1325143
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
Takifuji N; Fukuoka M; Negoro S; Takada M; Kusunoki Y; Matsui K; Masuda N; Ryu S; Sakai N; Kubota K
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):429-34. PubMed ID: 2157364
[TBL] [Abstract][Full Text] [Related]
17. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
[TBL] [Abstract][Full Text] [Related]
18. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C.
Hesketh PJ; Tansan S; Caguioa PB; Hesketh A; Blanchard R; DiMartino N; Carney D
Cancer; 1993 Feb; 71(3):717-20. PubMed ID: 8381703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
